NASDAQ:HRMY Harmony Biosciences (HRMY) Stock Forecast, Price & News $34.36 +0.61 (+1.81%) (As of 09/28/2023 ET) Add Compare Share Share Today's Range$32.94▼$34.6150-Day Range$31.89▼$39.0352-Week Range$29.81▼$62.08Volume565,840 shsAverage Volume678,653 shsMarket Capitalization$2.06 billionP/E Ratio10.51Dividend YieldN/APrice Target$60.78 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Harmony Biosciences MarketRank™ ForecastAnalyst RatingModerate Buy2.70 Rating ScoreUpside/Downside76.9% Upside$60.78 Price TargetShort InterestBearish21.64% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.56Based on 15 Articles This WeekInsider TradingN/AProj. Earnings Growth33.75%From $2.40 to $3.21 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.3.30 out of 5 starsMedical Sector7th out of 970 stocksPharmaceutical Preparations Industry1st out of 454 stocks 4.4 Analyst's Opinion Consensus RatingHarmony Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 8 buy ratings, 1 hold rating, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $60.78, Harmony Biosciences has a forecasted upside of 76.9% from its current price of $34.36.Amount of Analyst CoverageHarmony Biosciences has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted21.64% of the float of Harmony Biosciences has been sold short.Short Interest Ratio / Days to CoverHarmony Biosciences has a short interest ratio ("days to cover") of 13.8, which indicates bearish sentiment.Change versus previous monthShort interest in Harmony Biosciences has recently decreased by 5.04%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldHarmony Biosciences does not currently pay a dividend.Dividend GrowthHarmony Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HRMY. Previous Next 2.5 News and Social Media Coverage News SentimentHarmony Biosciences has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Harmony Biosciences this week, compared to 4 articles on an average week.Search InterestOnly 4 people have searched for HRMY on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows7 people have added Harmony Biosciences to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Harmony Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders28.40% of the stock of Harmony Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.23% of the stock of Harmony Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 4.4 Earnings and Valuation Earnings GrowthEarnings for Harmony Biosciences are expected to grow by 33.75% in the coming year, from $2.40 to $3.21 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Harmony Biosciences is 10.51, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 121.11.Price to Earnings Ratio vs. SectorThe P/E ratio of Harmony Biosciences is 10.51, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 129.73.Price to Earnings Growth RatioHarmony Biosciences has a PEG Ratio of 0.49. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioHarmony Biosciences has a P/B Ratio of 5.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Harmony Biosciences (NASDAQ:HRMY) StockHarmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. It offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.Read More HRMY Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HRMY Stock News HeadlinesSeptember 27, 2023 | msn.comGoldman Sachs Maintains Harmony Biosciences Holdings (HRMY) Sell RecommendationSeptember 26, 2023 | americanbankingnews.comHarmony Biosciences (NASDAQ:HRMY) Downgraded to "Sell" at The Goldman Sachs GroupSeptember 29, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...September 25, 2023 | msn.comGoldman Sachs Downgrades Harmony Biosciences Holdings (HRMY)September 25, 2023 | finance.yahoo.comShort seller petitions FDA to reverse approval of Harmony Biosciences drugSeptember 25, 2023 | finance.yahoo.comNike downgraded amid US wholesale pressures, China risks: 4 big analyst cutsSeptember 24, 2023 | americanbankingnews.comNeedham & Company LLC Reiterates "Buy" Rating for Harmony Biosciences (NASDAQ:HRMY)September 24, 2023 | americanbankingnews.comHarmony Biosciences (NASDAQ:HRMY) Sees Strong Trading VolumeSeptember 29, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...September 24, 2023 | seekingalpha.comHarmony Biosciences: A Balancing Act As Investors Lose Some SleepSeptember 20, 2023 | finance.yahoo.comHARMONY BIOSCIENCES PRESIDENT & CEO JEFFREY M. DAYNO, M.D., NAMED TO 2023 PHARMAVOICE 100 LIST OF TOP INDUSTRY LEADERSSeptember 20, 2023 | americanbankingnews.comHarmony Biosciences' (HRMY) Buy Rating Reaffirmed at MizuhoSeptember 15, 2023 | finance.yahoo.comThis Biotech Stock Pick Is Just Starting to Make Beautiful MusicSeptember 13, 2023 | finance.yahoo.comHARMONY BIOSCIENCES TO PARTICIPATE IN 2023 CANTOR GLOBAL HEALTHCARE CONFERENCESeptember 9, 2023 | msn.comBerenberg Initiates Coverage of Harmony Biosciences Holdings (HRMY) with Buy RecommendationSeptember 7, 2023 | markets.businessinsider.com9 Analysts Have This to Say About Harmony BiosciencesSeptember 7, 2023 | finance.yahoo.comHARMONY BIOSCIENCES ANNOUNCES US FOOD & DRUG ADMINISTRATION ORPHAN DRUG DESIGNATION FOR PITOLISANT FOR TREATMENT OF IDIOPATHIC HYPERSOMNIASeptember 7, 2023 | finance.yahoo.comHarmony Biosciences Holdings Inc (HRMY): A Deep Dive into Its Performance PotentialSeptember 6, 2023 | markets.businessinsider.comBerenberg Bank Reaffirms Their Buy Rating on Harmony Biosciences Holdings (HRMY)August 28, 2023 | seekingalpha.comHarmony Biosciences gains as challenge to Wakix patent rejectedAugust 28, 2023 | bizjournals.comHarmony Biosciences scores victory over activist short seller Scorpion with U.S. Patent Office decision on WakixAugust 28, 2023 | finance.yahoo.comHARMONY BIOSCIENCES REITERATES CONFIDENCE IN WAKIX® (PITOLISANT) PATENTS FOLLOWING FAVORABLE DECISION BY U.S. PATENT AND TRADEMARK OFFICE (USPTO) TO DENY PETITION FOR REEXAMINATIONAugust 28, 2023 | markets.businessinsider.comWill Harmony's INTUNE Trial Data Strike A Chord?August 23, 2023 | msn.comCantor Fitzgerald Reiterates Harmony Biosciences Holdings (HRMY) Overweight RecommendationAugust 22, 2023 | markets.businessinsider.comExpert Ratings for Harmony BiosciencesAugust 14, 2023 | markets.businessinsider.comHarmony Biosciences To Acquire Zynerba Pharma For Up To $200 MlnAugust 14, 2023 | msn.comZynerba Pharma (NASDAQ:ZYNE) Skyrockets 3x On Acquisition By Harmony Bio (NASDAQ:HRMY)See More Headlines Receive HRMY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Harmony Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address HRMY Company Calendar Last Earnings8/01/2023Today9/29/2023Next Earnings (Estimated)11/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:HRMY CUSIPN/A CIK1802665 Webwww.harmonybiosciences.com Phone484-539-9800FaxN/AEmployees200Year FoundedN/APrice Target and Rating Average Stock Price Forecast$60.78 High Stock Price Forecast$75.00 Low Stock Price Forecast$43.00 Forecasted Upside/Downside+76.9%Consensus RatingModerate Buy Rating Score (0-4)2.70 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)$3.27 Trailing P/E Ratio10.51 Forward P/E Ratio14.32 P/E Growth0.49Net Income$181.47 million Net Margins40.16% Pretax Margin26.85% Return on Equity42.49% Return on Assets25.49% Debt Debt-to-Equity Ratio0.37 Current Ratio4.90 Quick Ratio4.84 Sales & Book Value Annual Sales$437.86 million Price / Sales4.71 Cash Flow$3.55 per share Price / Cash Flow9.69 Book Value$6.79 per share Price / Book5.06Miscellaneous Outstanding Shares60,000,000Free Float42,960,000Market Cap$2.06 billion OptionableNot Optionable Beta0.43 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Jeffrey S. Aronin (Age 55)Founder & Non-Exec. Chairman Comp: $19.6kDr. Jeffrey M. Dayno M.D. (Age 66)Pres, CEO & Director Comp: $762.15kMr. Sandip S. Kapadia CPA (Age 53)M.B.A., Exec. VP & CFO Comp: $962.6kMr. Jeffrey Dierks M.B.A. (Age 51)Exec. VP & Chief Commercial Officer Comp: $662.1kMr. Andrew Serafin J.D. (Age 48)M.B.A., Exec. VP & Chief Strategy Officer Comp: $605.42kMr. David BradshawHead of Technical OperationsLuis SanayHead of Investor RelationsMr. Christian UlrichGen. Counsel & Corp. Sec.Ms. Tricia GloverChief Compliance OfficerMs. Audrey MurphyHead of HRMore ExecutivesKey CompetitorsVentyx BiosciencesNASDAQ:VTYXGemini TherapeuticsNASDAQ:GMTXSchrödingerNASDAQ:SDGRDynavax TechnologiesNASDAQ:DVAXGalapagosNASDAQ:GLPGView All CompetitorsInsiders & InstitutionsBarclays PLCBought 750 shares on 9/21/2023Ownership: 0.050%Perceptive Advisors LLCBought 791,370 shares on 8/24/2023Ownership: 1.486%Alberta Investment Management CorpSold 25,536 shares on 8/24/2023Ownership: 0.071%Virginia Retirement Systems ET ALBought 22,200 shares on 8/22/2023Ownership: 0.037%Teachers Retirement System of The State of KentuckyBought 519 shares on 8/21/2023Ownership: 0.016%View All Insider TransactionsView All Institutional Transactions HRMY Stock - Frequently Asked Questions Should I buy or sell Harmony Biosciences stock right now? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harmony Biosciences in the last twelve months. There are currently 1 sell rating, 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" HRMY shares. View HRMY analyst ratings or view top-rated stocks. What is Harmony Biosciences' stock price forecast for 2023? 10 Wall Street analysts have issued 1-year target prices for Harmony Biosciences' stock. Their HRMY share price forecasts range from $43.00 to $75.00. On average, they anticipate the company's share price to reach $60.78 in the next year. This suggests a possible upside of 76.9% from the stock's current price. View analysts price targets for HRMY or view top-rated stocks among Wall Street analysts. How have HRMY shares performed in 2023? Harmony Biosciences' stock was trading at $55.10 on January 1st, 2023. Since then, HRMY shares have decreased by 37.6% and is now trading at $34.36. View the best growth stocks for 2023 here. Are investors shorting Harmony Biosciences? Harmony Biosciences saw a decline in short interest during the month of September. As of September 15th, there was short interest totaling 7,350,000 shares, a decline of 5.0% from the August 31st total of 7,740,000 shares. Based on an average daily volume of 532,100 shares, the days-to-cover ratio is currently 13.8 days. Approximately 21.6% of the shares of the company are short sold. View Harmony Biosciences' Short Interest. When is Harmony Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023. View our HRMY earnings forecast. How were Harmony Biosciences' earnings last quarter? Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) announced its quarterly earnings results on Tuesday, August, 1st. The company reported $0.56 earnings per share for the quarter, missing the consensus estimate of $0.62 by $0.06. The company earned $134.22 million during the quarter, compared to analysts' expectations of $139.79 million. Harmony Biosciences had a net margin of 40.16% and a trailing twelve-month return on equity of 42.49%. What ETFs hold Harmony Biosciences' stock? ETFs with the largest weight of Harmony Biosciences (NASDAQ:HRMY) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), SPDR S&P Pharmaceuticals ETF (XPH), Virtus LifeSci Biotech Products ETF (BBP), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Invesco S&P SmallCap Health Care ETF (PSCH) and First Trust Nasdaq Pharmaceuticals ETF (FTXH).iShares U.S. Pharmaceuticals ETF (IHE). What other stocks do shareholders of Harmony Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Harmony Biosciences investors own include Advance Auto Parts (AAP), Advanced Micro Devices (AMD), Boeing (BA), Berry Global Group (BERY), Bunge (BG), Carrier Global (CARR), Commercial Metals (CMC), Canadian Solar (CSIQ), Deere & Company (DE) and Eastman Chemical (EMN). When did Harmony Biosciences IPO? (HRMY) raised $101 million in an initial public offering (IPO) on Wednesday, August 19th 2020. The company issued 4,700,000 shares at $20.00-$23.00 per share. Goldman Sachs, Jefferies and Piper Sandler served as the underwriters for the IPO. What is Harmony Biosciences' stock symbol? Harmony Biosciences trades on the NASDAQ under the ticker symbol "HRMY." How do I buy shares of Harmony Biosciences? Shares of HRMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Harmony Biosciences' stock price today? One share of HRMY stock can currently be purchased for approximately $34.36. How much money does Harmony Biosciences make? Harmony Biosciences (NASDAQ:HRMY) has a market capitalization of $2.06 billion and generates $437.86 million in revenue each year. The company earns $181.47 million in net income (profit) each year or $3.27 on an earnings per share basis. How many employees does Harmony Biosciences have? The company employs 200 workers across the globe. How can I contact Harmony Biosciences? Harmony Biosciences' mailing address is 630 W GERMANTOWN PIKE SUITE 215, PLYMOUTH MEETING PA, 19462. The official website for the company is www.harmonybiosciences.com. The company can be reached via phone at 484-539-9800 or via email at lcaperelli@harmonybiosciences.com. This page (NASDAQ:HRMY) was last updated on 9/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harmony Biosciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.